Last reviewed · How we verify
RotaTeq™ experimental formulation
RotaTeq is a live attenuated rotavirus vaccine that stimulates immune responses against rotavirus to prevent gastroenteritis.
RotaTeq is a live attenuated rotavirus vaccine that stimulates immune responses against rotavirus to prevent gastroenteritis. Used for Prevention of rotavirus gastroenteritis in infants and young children.
At a glance
| Generic name | RotaTeq™ experimental formulation |
|---|---|
| Also known as | V260 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated vaccine |
| Target | Rotavirus structural proteins (VP4, VP7) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
RotaTeq contains five live reassortant rotavirus strains (bovine-human hybrids) that replicate in the intestinal tract and induce both humoral and mucosal immunity against rotavirus. The vaccine generates antibodies and cellular immune responses that protect against infection and severe disease caused by wild-type rotavirus strains.
Approved indications
- Prevention of rotavirus gastroenteritis in infants and young children
Common side effects
- Diarrhea
- Vomiting
- Fever
- Irritability
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RotaTeq™ experimental formulation CI brief — competitive landscape report
- RotaTeq™ experimental formulation updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI